Yazar "Muderrisoglu, Haldun" seçeneğine göre listele

Listeleniyor 1 - 7 / 7
  • Küçük Resim
    Öğe
    Anticoagulants in left atrial thrombus resolution
    (2020) Yilmaz, Kerem Can; Ciftci, Orcun; Ozin, Bulent; Muderrisoglu, Haldun
    Aim: Warfarin has been used for protection from peripheral embolism in patients with atrial fibrillation (AF) and it has been shown that the direct oral anticoagulants are effective in protection against stroke as much as warfarin and cause lower bleeding complications. Our aim is to compare the efficacies of different anticoagulants in resolution of left atrial appendage thrombi.Materials and Methods: 264 patients were included in study. 39 patients had left atrial appendage thrombus; 17 patients underwent a repeat transesophageal echocardiography (TEE) after switching/administering an anticoagulant treatment regimen.Results: Thrombus was detected in 3 patients using apixaban, who were switched to dabigatran. Those patients were found to have thrombus resolution by the repeat TEE procedures. Of 5 patients using warfarin, 3 were switched to dabigatran, in one of whom thrombus resolution was not achieved. One patient continued warfarin with a target INR of 2.5-3.5 and a repeat TEE showed complete thrombus resolution. The remainder patient using warfarin was swithed to rivaroxaban, with complete thrombus resolution having been achieved. Two patients using edoxaban had their thrombi resolved by dabigatran. Seven patients were not receiving any anticoagulant regimen. Among these, warfarin was administered to 4 patients and apixaban to 2; repeat TEEs showed no thrombus. The remainder patient was administered low molecular weight heparin, and repeat TEE showed persistence of LAA thrombus.Conclusion: Irrespective of patients being anticoagulated, TEE should be planned before interventional procedures and cardioversion. If thrombus develops in a patient receiving anticoagulant treatment, switching to a different anticoagulant would be a logical option.
  • Küçük Resim Yok
    Öğe
    Clinical outcome of B2/C type isolated proximal LAD disease treated with drug-eluting stents
    (Aves Yayincilik, 2011) Cicek, Davran; Pekdemir, Hasan; Kalay, Nihat; Muderrisoglu, Haldun
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Efficacy of Sirolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in an Unselected Population With Coronary Artery Disease: 24-Month Outcomes of Patients in a Prospective Non-randomized Registry in Southern Turkey
    (Ivyspring Int Publ, 2010) Cicek, Davran; Pekdemir, Hasan; Kalay, Nihat; Binici, Sueleyman; Altay, Hakan; Muderrisoglu, Haldun
    Background: The efficacy of drug-eluting stents has been shown in randomized trials, but some controversy exists regarding which stent sirolimus-eluting or paclitaxel-eluting is more effective in unselected Turkish patients. Therefore, we investigated the clinical outcomes of patients who were treated with one type of these drug-eluting stents in the real world. Methods: We created a registry and prospectively analyzed data on a consecutive series of all patients who presented to our institution with symptomatic coronary artery disease between February 2005 and March 2007 and who were treated with the sirolimus- or the paclitaxel-eluting stent. The follow-up period after stent implantation was approximately 24 months. The primary end point was a major cardiac event, and the secondary end point was stent thrombosis. Informed consent was obtained from all subjects, and the study protocol was approved by the local ethical committee. Results: In total, 204 patients were treated with either the sirolimus-eluting stent (n = 103) or the paclitaxel-eluting stent (n = 101). The lesions in the 2 arms of the study were treated similarly by conventional technique. At 24-month follow-up, patients who received the paclitaxel-eluting stent showed significantly higher rates of non-Q-wave myocardial infarction (1.9% vs 5.9%; P: .002), target vessel revascularization (1.9% vs 4.9%; P: .002), coronary artery bypass graft surgery (1.9% vs 6.9%; P: .001), and late stent thrombosis (1.9% vs 3.9%, P: .002). Conclusions: Patients who received the sirolimus- eluting stent showed better clinical outcomes compared with those who had the paclitaxel-eluting-stent.
  • Küçük Resim
    Öğe
    Risk factors for coronary artery disease in left bundle branch block
    (2019) Yilmaz, Kerem Can; Keskin, Suzan; Ciftci, Orcun; Ozin, Bulent; Muderrisoglu, Haldun
    Aim: The presence of left bundle branch block (LBBB) in the surface electrocardiogram makes the evalaution of patients for suspected angina pectoris difficult. A newly developed LBBB in patients with acute chest pain is an indication for primary percutaneous coronary intervention. However, it is difficult to evaluate the coronary artery disease (CAD) in stable patients with LBBB. In this study, we aimed to investigate the baseline demographic characteristics, electrocardiographic and echocardiographic findings in LBBB patients who had a preliminary diagnosis of CAD. Material and Methods: We enrolled a total of 216 consecutive patients with a LBBB who had undergone coronary angiography. Of these patients, severe coronary artery disease did not find in 123 (56%) patients, while 93 (44%) patients had severe coronary artery disease Results: The frequency of male sex, diabetes mellitus and hyperlipidemia were significantly higher in the CAD group (p=0.007, p=0.001, and p=0.012, respectively). Comparasion of electrocardiographic findings revealed no significant difference betweent the goups. In terms of the echocardiography findings, the left venticular ejection fraction was significantly lower and the left venticular end-diastolic volume was significantly higher in patients with CAD. We noted that patients with CAD had significiantly elevated creatinine levels compared to those who did not. Conclusion: The significant risk factors for CAD among patients with LBBB included diabetes mellitus, elevated creatinine levels, male sex, advanced age, and low left venticular ejection fraction. These risk factors should be incorporated with non-invasive tests in patients with who had a preliminary diagnosis of CAD, and a conventional angiography should be considered in these patients in an attempt to increase the specificity and sensitivity of the available diagnostic tests.
  • Küçük Resim Yok
    Öğe
    Three Years Clinical Outcome of B2/C Type Isolated Proximal Left Anterior Descending Coronary Artery Disease in Elderly Patients Treated with Drug-Eluting Stents: A Prospective Single-Center Follow-Up Registry.
    (Excerpta Medica Inc-Elsevier Science Inc, 2011) Ciciek, Davran; Muderrisoglu, Haldun; Pekdemir, Hasan
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    TWO-YEAR OUTCOME OF TURKISH PATIENTS TREATED WITH ZOTAROLIMUS VERSUS PACLITAXEL ELUTING STENTS IN AN UNSELECTED POPULATION WITH CORONARY ARTERY DISEASE
    (Karger, 2010) Cicek, Davran; Pekdemir, Hasan; Kalay, Nihat; Binici, Suleyman; Altay, Hakan; Muderrisoglu, Haldun
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkey
    (Ivyspring Int Publ, 2011) Cicek, Davran; Pekdemir, Hasan; Haberal, Cevahir; Kalay, Nihat; Binici, Suleyman; Altay, Hakan; Muderrisoglu, Haldun
    Background: Our purpose was to investigate the clinical outcomes of Zotarolimus- and Paclitaxel-eluting stents in Turkish patients with coronary artery disease (CAD). In general, the outcome of drug-eluting stent (DES) placement has a proven efficacy in randomized trials. However, the difference in efficacy between the Zotarolimus and Paclitaxel-eluting stents in unselected Turkish patients is controversial. Therefore, we investigated the clinical outcomes of these two drug-eluting stents in the real-world. Methods: We created a registry and prospectively analyzed data on a consecutive series of all patients who presented to our institution with symptomatic coronary artery disease between February 2005 and March 2007 and who were treated with the zotarolimus- or the paclitaxel-eluting stent. The follow-up period was approximately two years. The primary end-point was major cardiac events, and the secondary end-point was definite stent thrombosis. Informed consent was obtained from all subjects, and the study protocol was approved by the local ethical committee. Results: In total, 217 patients were treated with either the zotarolimus-eluting stent (n = 116) or the paclitaxel-eluting stent (n = 101). The lesions in the 2 arms of the study were treated similarly by conventional technique. At 24-month follow-up the paclitaxel-eluting stent group showed significantly higher non-Q wave myocardial infarction (2.6% vs 5.9%, p: 0.02), Q wave myocardial infarction (1.7% vs 5.9%, p: 0.049), coronary artery binding graft surgery (2.6% vs 6.9%, p: 0.002), and late stent thrombosis (1.7% vs 3.9%, p: 0.046). Conclusions: Zotarolimus-eluting stents demonstrated better clinical outcomes than Paclitaxel- eluting stents in a daily routine practice of coronary intervention in an unselected Turkish population.